Business Wire

Corona, The World’s Most Valuable Beer Brand1, Announces Its 100-Year Anniversary with Global Celebration

25.4.2025 10:00:00 CEST | Business Wire | Press release

Share

Brand Invites The World to Join the Celebration with Experiences at the Most Epic Beaches on EarthGlobal “Corona 100” Platform Launches with a Legendary Concert at Copacabana Beach, Featuring One of the World’s Top Musical Artists with Millions in Attendance

Today, Corona proudly celebrates its 100-year anniversary, a remarkable milestone for the iconic brand that has been synonymous with the beach and enjoyed by consumers worldwide for the past century. Since 1925, Corona has cultivated a deep association with the beach; fully embodying a lifestyle connected to nature and relaxation.

This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20250425804516/en/

Corona 100 This Is Living Since 1925

In honor of the occasion, Corona invites everyone to live their “beach side” – a.k.a. their best side – at top-tier beach locations across the globe. The Corona 100 platform includes a film highlighting 100 years of beach culture, a definitive list of the top 100 beaches in the world to visit, and a signed multi-year sponsorship of a renowned concert at Copacabana Beach in Rio de Janeiro — all offering people across the globe opportunities to connect with their beach side.

“For 100 years, Corona has fully embodied the ‘This is Living’ spirit of the beach lifestyle, inspiring people to disconnect from their everyday routine and reconnect with nature and each other,” said Clarissa Pantoja, Global VP of Corona. “Enjoyed by millions around the world today and still growing, Corona will always remain unwavering in its commitment to the beach. This anniversary is not just a celebration of our legacy, but also a call for everyone to embrace their best side – the beach side – both now and for the next 100 years to follow.”

100 Years, 100 Iconic Beaches

To honor a century of beach side living, the brand has created its CoronaBeach 100list: a curated guide of the world’s most iconic beaches that best represent Corona’s “This is Living” expression. From hidden coves to legendary coastlines to remote paradises, these beaches aren’t just destinations; they’re places where people have traveled for centuries to disconnect from the real world and reconnect with nature.

The guide includes sandy beaches from famed hotspots within South Africa, Mexico, and Brazil, as well as showcases some lesser traveled shorelines, such as Chile’s Punta de Lobos, Iceland’s Stokksnes Beach, and Canada’s Cox Bay Beach, among many more.

Additionally, Corona is offering the chance to visit the iconic beaches featured on the Beach 100 list. Anyone of legal drinking age can enter to win a chance to tap into their beach side at one of the 100 crowned coastlines simply by purchasing the special edition 100 Anniversary pack and scanning the QR code. Other instant win items include Corona merchandise, coolers, towels, and digital vouchers.

To build the guide, Corona assembled a panel of beach experts, comprised of oceanographers, surfers, free divers, and other nature enthusiasts to curate the list, all who meticulously rated hundreds of the world’s beaches using a carefully curated set of criteria. Each beach in the Corona Beach 100 is “Sun Awarded” – rated between one to three suns – and recognizes the locations that embody the true spirit of “This is Living” based on three essential elements: Beachside Culture, Connection to Nature, and Scenic Aesthetics.

To access the Beach 100 list – developed in partnership with experiential marketing agency, WINK – and to learn more about how to win Beach 100 prizes, visit Corona.com for more information.

Cheers to 100 Years at Copacabana Beach

To kick-off the anniversary in grand fashion, Corona will take over one of the most iconic beaches in the world – Copacabana Beach in Rio De Janeiro – as a marquee sponsor of a global concert that will transform the shores of Copacabana Beach into the ultimate celebration. Taking place on May 3rd, the concert will captivate millions of attendees on the beach where each year the concert will feature some of the world’s most popular musical artists and bands.

A Century of Beach Culture

From its origins in Mexico in 1925, Corona has been dedicated to quality with an emphasis on how the beach lifestyle positively impacts consumers worldwide. Named the World’s Most Valuable Beer Brand1 in 2024, Corona has turned every sip into a moment of connection through its premium products – brewed with 100% natural ingredients including its iconic lime ritual – and continues to bring more “This is Living” moments of social connection and relaxation into the world.

To highlight those 100 years of beach culture, Corona has unveiled a branded legacy film, titled “This is Living Since 1925," that brings to life many decades unfolding over the course of a day. From the early beginnings of beach side gatherings during the bikini era to swimming and surfing across the globe today, the archival look and feel across the film sets the tone for each decade, which also depicts a variety of beaches and coastlines from around the world.

As seen in the film – created in partnership with Wieden+Kennedy Amsterdam – Corona’s integration within the beach culture is effortless in the scenes over time, a testament to the brand’s natural place on the beach “Since 1925.”

The 360 platform also features vibrant new digital, trade, and OOH assets that highlight how Corona has remained a staple for beach lovers from around the world for generations — no matter the season or location.

The centennial celebrations will continue throughout 2025, so grab a lime, raise a Corona, and join the brand in commemorating a century of vibrant beachside living. Cheers to 100 years under the sun and to the next century of unforgettable "This Is Living" moments.

About Corona Global

Corona, an AB InBev global brand*, is the iconic beer brand that is synonymous with paradise with a presence in 180 countries. Recognized as the world’s most valuable beer brand in Kantar’s BrandZ global 2024 rankings, Corona invites the world outside, beckoning you to reconnect with your essential nature and embrace the simple pleasures of life. But it's not just about the beer – it's about the ritual. The ritual of adding a slice of lime to your Corona, an experience that elevates the moment. Corona isn't just a beverage; it's nature in a bottle. And we strive to help protect nature and have become the first global beverage brand with a net-zero plastic footprint. This builds on our longstanding ambition to help protect the world’s oceans and beaches from plastic pollution. Every sip of Corona is a celebration of nature and the beauty of the world around us.

*Corona is not sold by AB InBev in the United States.

About AB InBev

Anheuser-Busch InBev (AB InBev) is a publicly traded company (Euronext: ABI) based in Leuven, Belgium, with secondary listings on the Mexico (MEXBOL: ANB) and South Africa (JSE: ANH) stock exchanges and with American Depositary Receipts on the New York Stock Exchange (NYSE: BUD). As a company, we dream big to create a future with more cheers. We are always looking to serve up new ways to meet life’s moments, move our industry forward and make a meaningful impact in the world. We are committed to building great brands that stand the test of time and to brewing the best beers using the finest ingredients. Our diverse portfolio of well over 500 beer brands includes global brands Budweiser®, Corona®, Stella Artois® and Michelob Ultra®; multi-country brands Beck’s®, Hoegaarden® and Leffe®; and local champions such as Aguila®, Antarctica®, Bud Light®, Brahma®, Cass®, Castle®, Castle Lite®, Cristal®, Harbin®, Jupiler®, Modelo Especial®, Quilmes®, Victoria®, Sedrin®, and Skol®. Our brewing heritage dates back more than 600 years, spanning continents and generations. From our European roots at the Den Hoorn brewery in Leuven, Belgium. To the pioneering spirit of the Anheuser & Co brewery in St. Louis, US. To the creation of the Castle Brewery in South Africa during the Johannesburg gold rush. To Bohemia, the first brewery in Brazil. Geographically diversified with a balanced exposure to developed and developing markets, we leverage the collective strengths of approximately 144 000 colleagues based in nearly 50 countries worldwide. For 2024, AB InBev’s reported revenue was 59.8 billion USD (excluding JVs and associates).

1Kantar BrandZ 2024 Global Rankings

View source version on businesswire.com: https://www.businesswire.com/news/home/20250425804516/en/

Subscribe to releases from Business Wire

Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.

Latest releases from Business Wire

International Human Rights Lawyer Jared Genser and Former White House Counsel Lanny J. Davis Join Legal and Advocacy Team Supporting Cambodian Businessman Yim Leak, Seiden Law LLP Announces18.9.2026 19:52:00 CEST | Press release

Jared Genser, one of the world's most recognized international human rights lawyers, and Lanny J. Davis, an adviser to former presidents George W. Bush and Bill Clinton, join the legal and advocacy team for Cambodian businessman Yim Leak and challenge what they call a coordinated smear campaign in Thailand. International human rights lawyer Jared Genser and Lanny J. Davis, who has close ties to two former US presidents and a worldwide reputation for defending those under attack with lies and smears, and for repairing the damage done to their reputations, have joined the legal and advocacy team supporting Cambodian businessman Yim Leak, Seiden Law LLP, which serves as Yim Leak's chief global counsel, announced today. Their first move is to hold the Thai government accountable, framing its conduct as either complicit in or willfully blind to a sustained smear campaign against Yim. Genser is Managing Director of Perseus Strategies, an international law firm. Over more than two decades, he

Ningbo FEED Meeting Confirms Full Confidence in Q1 2027 FID for Allied Biofuels’ US$6.1 Billion Presidential Decree-Backed SAF and e-SAF Project18.9.2026 17:38:00 CEST | Press release

Allied Biofuels has held a major Front-End Engineering Design (FEED) meeting at Sinopec’s office in Ningbo, China, bringing together Allied Biofuels, Sinopec Engineering Group Co., Ltd. of China, Topsoe A/S of Denmark, Sasol South Africa Limited, and Plug Power of the United States — the principal international engineering and technology providers supporting its US$6.1 billion Presidential Decree-backed Sustainable Aviation Fuel (SAF) and e-SAF project in Uzbekistan. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260918708077/en/ FEED Meeting - Ningbo, China At the joint FEED meeting of the project’s core engineering and technology stakeholders, the discussions established clear alignment on engineering responsibilities, technology interfaces, design deliverables, project integration and the coordinated execution programme required to advance the project through FEED. All stakeholders working on the project expressed full co

Corcept Announces CHMP Opinion Recommending EU Marketing Authorization for Lifyorli® (Relacorilant)18.9.2026 14:00:00 CEST | Press release

Corcept Therapeutics Incorporated (NASDAQ: CORT), a commercial-stage company engaged in the discovery and development of medications to treat severe endocrinologic, oncologic, metabolic and neurologic disorders by modulating the effects of the hormone cortisol, today announced that the European Medicines Agency’s Committee for Medicinal Products for Human Use (CHMP) has recommended that the European Commission (EC) should approve relacorilant, combined with the chemotherapy drug nab-paclitaxel, for the treatment of patients with platinum-resistant ovarian cancer. The CHMP’s recommendation is based on positive data from Corcept’s Phase 2 and pivotal Phase 3 ROSELLA trials, in which patients receiving relacorilant combined with nab-paclitaxel experienced improved progression-free and overall survival compared to patients who received nab-paclitaxel alone. The safety profile of relacorilant plus nab-paclitaxel in these trials was consistent with the safety profile of nab-paclitaxel monoth

Enhertu® Recommended for Approval in the EU by CHMP as Adjuvant Treatment for Patients with Residual Disease After Neoadjuvant Treatment for HER2 Positive Early Breast Cancer18.9.2026 14:00:00 CEST | Press release

Recommendation based on DESTINY-Breast05 phase 3 trial results that showed Enhertu reduced the risk of invasive disease recurrence or death by 53% versus T-DM1 Daiichi Sankyo and AstraZeneca’s Enhertu has the potential to become a new standard of care in this early breast cancer setting Enhertu® (trastuzumab deruxtecan) has been recommended for approval in the European Union (EU) as a monotherapy for the adjuvant treatment of adult patients with resected HER2 positive breast cancer who have residual invasive disease after neoadjuvant taxane-based and HER2 targeted treatment. Enhertu is a specifically engineered HER2 directed DXd antibody drug conjugate (ADC) discovered by Daiichi Sankyo (TSE: 4568) and being jointly developed and commercialized by Daiichi Sankyo and AstraZeneca (LSE/STO/NYSE: AZN). The Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) based its positive opinion on results from the DESTINY-Breast05 phase 3 trial presented at th

CHMP Recommends EU Approval of New Indication for Alfasigma’s Jyseleca® (filgotinib), Treatment of Adults With Axial Spondyloarthritis18.9.2026 12:58:00 CEST | Press release

The information contained within this press release is for the purpose of scientific exchange.It is intended for scientific, financial and investor media only.If approved, Jyselecawill be indicated for the treatment of patients with active axial spondyloarthritis (axSpA), both non-radiographic and radiographic forms of the disease, who have responded inadequately to conventional therapy.Despite the availability of multiple treatment options, nearly half of people living with axSpA do not respond adequately to current therapies, and just 10-20% reach inactive disease within 16-24 weeks of initiating treatment.CHMP’s positive opinion is based on findings from the OLINGUITO Phase 3 study, where improvements in the signs and symptoms of axSpA with filgotinib were observed early and maintained over 52 weeks of treatment.Jyselecais already approved in Europe and the United Kingdom, for the treatment of moderate to severe rheumatoid arthritis and ulcerative colitis. Alfasigma S.p.A, a global

In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.

Visit our pressroom
World GlobeA line styled icon from Orion Icon Library.HiddenA line styled icon from Orion Icon Library.Eye